Увійти

Готові списки джерел за темами / Diabetic Chronic Kidney Disease / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Diabetic Chronic Kidney Disease.

Статті в журналах з теми "Diabetic Chronic Kidney Disease"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Diabetic Chronic Kidney Disease".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Yee, J. "Diabetic Kidney Disease: Chronic Kidney Disease and Diabetes." Diabetes Spectrum 21, no. 1 (2008): 8–10. http://dx.doi.org/10.2337/diaspect.21.1.8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Shafi, Salman Tahir, Mohammad Saleem, Wajid Abdullah, Roshina Anjum, and Tahir Shafi. "CHRONIC KIDNEY DISEASE." Professional Medical Journal 23, no. 09 (2016): 1104–9. http://dx.doi.org/10.29309/tpmj/2016.23.09.1706.

Повний текст джерела

Анотація:

Diabetes Mellitus and Hypertension are leading causes of chronic kidneydisease (CKD). There is limited data on frequency of retinopathy attributed to diabetes mellitusor hypertension in CKD patients in local population. Objective: to determine the frequency ofdiabetic and hypertensive retinopathy in patients with CKD not on hemodialysis or peritonealdialysis. Study Design: Cross Sectional. Setting: Nephorology ward at Sharif Medical CityHospital. Period: 6 Month. Methods: All patients between ages of 20-80 years with CKD notpreviously on renal replacement therapy (hemodialysis or peritoneal di

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Punit, Kumar1* Vipul Gupta2 Pranav Gupta3 Reena Tiwari4 Timur Beisenov1. "A Concise Review Study on Diabetic Nephropathy: Risk Factors, Pathogenesis, and Treatment." International Journal of Medical Science in Clinical Research and Review 7, no. 06 (2024): 1358–64. https://doi.org/10.5281/zenodo.14211102.

Повний текст джерела

Анотація:

<strong><u>ABSTRACT</u></strong>: Diabetes-related kidney disease is known as diabetic nephropathy (DN). It is also known as renal disease and manifests progressively over many years. It is assumed that DN will require therapy for about one in five diabetics. In developed countries, diabetic kidney disease is assumed as mainly responsible for end-stage kidney disease. It is suggested that about 40% of cases of diabetes are prone to diabetic kidney diseases. Thus, the incidence of increasing cases of this disease is linked to diabetic patients. Proteinuria is also an important indicator of diab

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Williams, Mark E. "Diabetic Chronic Kidney Disease." Medical Clinics of North America 97, no. 1 (2013): xi—xii. http://dx.doi.org/10.1016/j.mcna.2012.11.005.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Rini, Sulistio, Suharyo Hadisaputro, Lestariningsih Lestariningsih, Heri Nugroho, and Selamat Budijitno. "Faktor Risiko Penyakit Ginjal Kronik Diabetes (PGK-DM) pada Diabetes Mellitus Tipe-2 (Studi di RSUD DR Soedarso Kota Pontianak Provinsi Kalimantan Barat)." Jurnal Epidemiologi Kesehatan Komunitas 3, no. 1 (2018): 101. http://dx.doi.org/10.14710/j.e.k.k.v3i1.4028.

Повний текст джерела

Анотація:

Background: Prevalence of type-2 diabetes mellitus have increased signiﬁcantly. The increasing number of people with diabetes has a major impact on the development of chronic diabetic kidney disease. The research was aimed to clarify several risk factors of chronic diabetic kidney disease on type-2 diabetes mellitus (CDK-DM).Method: The research was based on case control study design. The number of respondents was 140 respondents consisting 70 cases and 70 controls that met the criteria of inclusion and exclusion. The cases were patients with type-2 chronic diabetic kidney disease stadium 2-5.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Rini, Sulistio, Suharyo Hadisaputro, Lestariningsih Lestariningsih, Heri Nugroho, and Selamat Budijitno. "Faktor Risiko Penyakit Ginjal Kronik Diabetes (PGK-DM) pada Diabetes Mellitus Tipe-2 (Studi di RSUD DR Soedarso Kota Pontianak Provinsi Kalimantan Barat)." Jurnal Epidemiologi Kesehatan Komunitas 3, no. 2 (2018): 101. http://dx.doi.org/10.14710/j.e.k.k.v3i2.4029.

Повний текст джерела

Анотація:

Background: Prevalence of type-2 diabetes mellitus have increased signiﬁcantly. The increasing number of people with diabetes has a major impact on the development of chronic diabetic kidney disease. The research was aimed to clarify several risk factors of chronic diabetic kidney disease on type-2 diabetes mellitus (CDK-DM).Method: The research was based on case control study design. The number of respondents was 140 respondents consisting 70 cases and 70 controls that met the criteria of inclusion and exclusion. The cases were patients with type-2 chronic diabetic kidney disease stadium 2-5.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Rini, Sulistio, Suharyo Hadisaputro, Lestariningsih Lestariningsih, Heri Nugroho, and Selamat Budijitno. "Faktor Risiko Penyakit Ginjal Kronik Diabetes (PGK-DM) pada Diabetes Mellitus Tipe-2 (Studi di RSUD DR Soedarso Kota Pontianak Provinsi Kalimantan Barat)." Jurnal Epidemiologi Kesehatan Komunitas 3, no. 1 (2018): 101. http://dx.doi.org/10.14710/jekk.v3i1.4028.

Повний текст джерела

Анотація:

Background: Prevalence of type-2 diabetes mellitus have increased signiﬁcantly. The increasing number of people with diabetes has a major impact on the development of chronic diabetic kidney disease. The research was aimed to clarify several risk factors of chronic diabetic kidney disease on type-2 diabetes mellitus (CDK-DM).Method: The research was based on case control study design. The number of respondents was 140 respondents consisting 70 cases and 70 controls that met the criteria of inclusion and exclusion. The cases were patients with type-2 chronic diabetic kidney disease stadium 2-5.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Rini, Sulistio, Suharyo Hadisaputro, Lestariningsih Lestariningsih, Heri Nugroho, and Selamat Budijitno. "Faktor Risiko Penyakit Ginjal Kronik Diabetes (PGK-DM) pada Diabetes Mellitus Tipe-2 (Studi di RSUD DR Soedarso Kota Pontianak Provinsi Kalimantan Barat)." Jurnal Epidemiologi Kesehatan Komunitas 3, no. 2 (2018): 101. http://dx.doi.org/10.14710/jekk.v3i2.4029.

Повний текст джерела

Анотація:

Background: Prevalence of type-2 diabetes mellitus have increased signiﬁcantly. The increasing number of people with diabetes has a major impact on the development of chronic diabetic kidney disease. The research was aimed to clarify several risk factors of chronic diabetic kidney disease on type-2 diabetes mellitus (CDK-DM).Method: The research was based on case control study design. The number of respondents was 140 respondents consisting 70 cases and 70 controls that met the criteria of inclusion and exclusion. The cases were patients with type-2 chronic diabetic kidney disease stadium 2-5.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

R Shinde, Shruti, Avinash Chaudhari, and Amar Kulkarni. "Study of Thyroid Profile in Diabetic Versus Non - Diabetic Chronic Kidney Disease Patients." International Journal of Science and Research (IJSR) 13, no. 8 (2024): 1517–22. http://dx.doi.org/10.21275/sr24825130803.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Klimontov, V. V., and A. I. Korbut. "Normoalbuminuric chronic kidney disease in diabetes." Terapevticheskii arkhiv 90, no. 10 (2018): 94–98. http://dx.doi.org/10.26442/terarkh201890104-98.

Повний текст джерела

Анотація:

Urinary albumin excretion (UAE) is widely used in clinical practice as indicator of diabetic kidney disease. According to the classical concept of the natural course of diabetic nephropathy, an increase in UAE usually precedes a decline in renal function. Meanwhile, a growing body of evidences indicates a high prevalence of normoalbuminuric chronic kidney disease (NA-CKD) in diabetic subjects, especially among patients with type 2 diabetes. An increase in NA-CKD prevalence can be results of improved glucose, blood pressure, and lipid control, widespread use of renin-angiotensin system blockers

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Lecamwasam, Ashani, Tiffanie M. Nelson, Leni Rivera, Elif I. Ekinci, Richard Saffery, and Karen M. Dwyer. "Gut Microbiome Composition Remains Stable in Individuals with Diabetes-Related Early to Late Stage Chronic Kidney Disease." Biomedicines 9, no. 1 (2020): 19. http://dx.doi.org/10.3390/biomedicines9010019.

Повний текст джерела

Анотація:

(1) Background: Individuals with diabetes and chronic kidney disease display gut dysbiosis when compared to healthy controls. However, it is unknown whether there is a change in dysbiosis across the stages of diabetic chronic kidney disease. We investigated a cross-sectional study of patients with early and late diabetes associated chronic kidney disease to identify possible microbial differences between these two groups and across each of the stages of diabetic chronic kidney disease. (2) Methods: This cross-sectional study recruited 95 adults. DNA extracted from collected stool samples were

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Ahmed, Medina Abdela, Yohannes Mulu Ferede, and Wubet Worku Takele. "Incidence and predictors of chronic kidney disease in type-II diabetes mellitus patients attending at the Amhara region referral hospitals, Ethiopia: A follow-up study." PLOS ONE 17, no. 1 (2022): e0263138. http://dx.doi.org/10.1371/journal.pone.0263138.

Повний текст джерела

Анотація:

Background Chronic kidney disease (CKD) is the severest form of kidney disease characterized by poor filtration. The magnitude of chronic kidney disease is trending upward in the last few years linked with the rapidly escalating cases of non-communicable chronic diseases, particularly diabetes mellitus. However, little is known about when this problem may occur, the incidence as well as predictors of chronic kidney disease among type-II diabetes mellitus patients. Thus, this study was conducted to determine the incidence, time to the occurrence, and predictors of chronic kidney disease in type

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Najar, M. Saleem, and Khurshid A. Banday. "Diabetic Kidney Disease, We Need to Act Fast." JMS SKIMS 13, no. 1 (2010): 1–3. http://dx.doi.org/10.33883/jms.v13i1.193.

Повний текст джерела

Анотація:

Diabetes is the leading cause of end-stage kidney failure throughout the world in both developed and developing countries.' The same is now true of Kashmir Valley also. In a study conducted in 1999 amongst 780 patients of chronic kidney disease in the only nephrology unit of the Valley, chronic glomerulonephritis was the commonest cause of chronic kidney disease constituting 33% of the total number.2 But a decade latter in another study diabetes was the leading cause of chronic kidney disease and accounting for 33.3% of the total number.It is very important to alert doctors, patients and gover

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Dong, Yi-jun, Nian Liu, Zhi Xiao, et al. "Renal Protective Effect of Sirtuin 1." Journal of Diabetes Research 2014 (2014): 1–8. http://dx.doi.org/10.1155/2014/843786.

Повний текст джерела

Анотація:

Silent information regulator 2 (Sir2) is a nicotinamide adenine dinucleotide- (NAD+-) dependent deacetylase. The homology of SIRT1 and Sir2 has been extensively studied. SIRT1 deacetylates target proteins using the coenzyme NAD+and is therefore linked to cellular energy metabolism and the redox state through multiple signalling and survival pathways. During the past decade, investigators have reported that SIRT1 activity is essential in cancer, neurodegenerative diseases, diabetes, cardiovascular disease, and other age-related diseases. In the kidneys, SIRT1 may inhibit renal cell apoptosis, i

Стилі APA, Harvard, Vancouver, ISO та ін.

15

BELLO, Ruth Eleojo, and Ruth Oluyomi OLORUNMONU. "Prevalence of Chronic Kidney Disease in University of Ilorin Teaching Hospital, Ilorin Kwara State, Nigeria." International Journal of Medicine, Nursing & Health Sciences (IJMNHS) ® 3, no. 4 (2022): 1–13. https://doi.org/10.5281/zenodo.7025169.

Повний текст джерела

Анотація:

Chronic kidney disease (CKD) is an increasingly prevalent problem worldwide. Treatment of end stage kidney disease is beyond the reach of an average Nigerian. The prevention and early detection are imperative to reducing its burden. The aim of this study was to determine the prevalence of chronic kidney disease in University of Ilorin Teaching Hospital, Ilorin Kwara state. It was a retrospective study of patients with chronic kidney disease managed in University of Ilorin Teaching Hospital, Ilorin Kwara state over a 36-month period from January 2017 to December 2019. Relevant data were collect

Стилі APA, Harvard, Vancouver, ISO та ін.

16

El Boustany, Ray. "Vasopressin and Diabetic Kidney Disease." Annals of Nutrition and Metabolism 72, Suppl. 2 (2018): 17–20. http://dx.doi.org/10.1159/000488124.

Повний текст джерела

Анотація:

Background: Diabetic nephropathy has become the most common cause of chronic kidney disease (CKD). Despite the progress accomplished in therapy, the prevalence of renal disorders remains high. Some modifiable factors driving the increase in incidence of CKD, in diabetes and other settings, might have been overlooked. Consistent evidence supports a role for vasopressin, hydration state, and urine concentration in kidney health. Summary: Plasma vasopressin is elevated in diabetes, even if metabolic control is good. Several epidemiological studies have pointed to a positive association between ma

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Akram, Muhammad, Tahmina Maqbool, Mohammed Khudhair Hasan, et al. "Managing Diabetes Mellitus in Chronic Kidney Disease: Approaches." African Journal of Clinical Medicine and Pharmacy Research 2, no. 2 (2025): 239–46. https://doi.org/10.58578/ajcmpr.v2i2.5222.

Повний текст джерела

Анотація:

The main objective of this article is to review the medical management of the disease known as “diabetes mellitus” and its general consequences. To assess the risks and benefits of intensive glycemic control in patients with diabetic kidney disease, the search was refined using the following specific terms: “diabetic nephropathy” and “kidney disease”, as well as “diabetes management” and “antidiabetic agents” or “oral hypoglycemic agents”. A unique challenge. Due to changes in insulin production, glucose transport and metabolism, impaired renal function is associated with hyperglycemia and hyp

Стилі APA, Harvard, Vancouver, ISO та ін.

18

U, Bhavana. "Antidiabetic Therapy in Patients Related to CKD (Chronic Kidney Disease)." Diabetes & Obesity International Journal 8, no. 4 (2023): 1–16. http://dx.doi.org/10.23880/doij-16000282.

Повний текст джерела

Анотація:

Patients with type 2 diabetes mellitus (T2DM) are more likely to have chronic kidney disease (CKD) in stages 3-5 (glomerular filtration rate [GFR] 60 mL/min) by roughly 25–30%. Despite the limits of most oral anti-diabetic medications in people with CKD, incretin-based treatments are being utilized more frequently to treat type 2 diabetes. This study examines the impact of CKD on the pharmacokinetics of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, as well as the efficacy/safety profile of these medications when used in patients with T2DM and

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Margaryan, Arus Garikovna, Svetlana Anatolievna Lebedeva, Dariya Mikhailovna Lisitsyna, Polina Igorevna Sirotkina, Lyudmila Aleksandrovna Yakubova, and Vadim Vladimirovich Tarasov. "Role of vasopressin signaling in the pathogenesis of diabetic nephropathy." Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology), no. 6 (September 15, 2021): 9–20. http://dx.doi.org/10.33920/med-13-2112-01.

Повний текст джерела

Анотація:

The diabetic kidney disease (also known as diabetic nephropathy) is a major complication of diabetes mellitus and also the most common cause of chronic kidney disease. Elevated plasma levels of vasopressin are consistently observed in patients with either type 1 and type 2 diabetes mellitus and in animal models of diabetes mellitus. A role of enhanced vasopressin signaling in progression of the diabetic nephropathy to chronic kidney disease has been suggested in several epidemiological studies but the underlying pathogenetic mechanisms remain largely unclear and are the subject of current scie

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Polyakov, V. K., A. V. Shutrova, N. V. Bolotova, N. Yu Filina, N. Yu Raygorodskaya, and E. G. Dronova. "Diagnosis of diabetic nephropathy and chronic kidney disease in prepubertal children with type 1 diabetes mellitus." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 67, no. 1 (2022): 82–88. http://dx.doi.org/10.21508/1027-4065-2022-67-1-82-88.

Повний текст джерела

Анотація:

The state of renal function in children with type 1 diabetes mellitus and small, up to 5 years old, disease experience was studied. The aim of the study was to determine the indicators of the initial stages of the formation of diabetic nephropathy and chronic kidney disease. A prospective cohort study of a group of 46 prepubertal patients with type 1 diabetes mellitus and less than 5 years of illness was carried out. Diabetic nephropathy at the stage of microalbuminuria was detected already in 8% of children. Signs of the first, preclinical stage of chronic kidney disease, manifested by hyperf

Стилі APA, Harvard, Vancouver, ISO та ін.

21

RT Lakey, Jonathan, Zach Villaverde, Tori Tucker, Michael Alexander, and Scott A. Hepford. "Improved Kidney Function Following Physiologic Insulin Resensitization Treatment Modality." Endocrinology and Disorders 5, no. 4 (2021): 01–04. http://dx.doi.org/10.31579/2640-1045/080.

Повний текст джерела

Анотація:

Diabetes affects millions of people worldwide and is a leading cause of amputation, blindness, neuropathy, and chronic kidney disease. Chronic kidney disease results in the prolonged impairment of kidney function. Common medications and lifestyle modifications do not eliminate the long-term complications of diabetes, because they lack the ability to restore the periodic cycle of insulin that exists in healthy physiology. Our study used a precise administration of exogenous insulin, mimicking the physiologic profile of insulin secretion, which is more effective at stabilizing cellular blood glu

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Lavoz, Carolina, Sandra Rayego-Mateos, Macarena Orejudo, et al. "Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?" Journal of Clinical Medicine 9, no. 1 (2020): 272. http://dx.doi.org/10.3390/jcm9010272.

Повний текст джерела

Анотація:

Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been u

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Yerokhovych, Viktoriia, Nazrin Tahiieva, and Iuliia Komisarenko. "The Role of Aldosterone in the Development of Chronic Kidney Disease in Individuals with Type 2 Diabetes." Ukrainian Scientific Medical Youth Journal 152, no. 1 (2025): 147–53. https://doi.org/10.32345/usmyj.1(152).2025.147-153.

Повний текст джерела

Анотація:

modern statistics confirm that diabetes has become an epidemic of the 21st century. According to the forecasts of the International Diabetes Federation, by 2045, the number of people with diabetes is expected to reach 784 million. Approximately 90% of cases involve type 2 diabetes, which is a major contributor to the development of chronic kidney and cardiovascular diseases. The role of aldosterone in the progression of persistent kidney filtration rate disorders is particularly important due to the high prevalence of microvascular complications in individuals with type 2 diabetes, especially

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Kin Tekce, Buket, Hikmet Tekce, Gulali Aktas, and Mustafa Sit. "Evaluation of the Urinary Kidney Injury Molecule-1 Levels in Patients With Diabetic Nephropathy." Clinical & Investigative Medicine 37, no. 6 (2014): 377. http://dx.doi.org/10.25011/cim.v37i6.22242.

Повний текст джерела

Анотація:

Purpose: Kidney Injury Molecule-1 is a protein that increases in urine following tubular damage. Kidney Injury Molecule-1 levels were correlated with the level of chronic kidney disease secondary to diabetic nephropathy in patients with type 2 Diabetes Mellitus. Methods: Clinical and laboratory findings of 142 patients with diabetic nephropathy and 34 control subjects were analysed. Creatinine and HbA1c levels in blood samples and albumin, creatinine and Kidney Injury Molecule-1 levels in urine samples were assessed. Results: Urinary Kidney Injury Molecule-1 levels were significantly increased

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Kaul, Anupama, and Amit Kumar Mahapatra. "Chronic kidney disease–mineral bone disorders in diabetic kidney disease." Clinical Queries: Nephrology 1, no. 2 (2012): 134–37. http://dx.doi.org/10.1016/s2211-9477(12)70007-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Ateş, İhsan, Nihal Özkayar, Mehmet Fettah Arıkan, Canan Topçuoğlu, and Fatih Dede. "The Serum Irisin Level in Non-Diabetic Patients with Chronic Kidney Disease." Turkish Nephrology Dialysis Transplantation 26, no. 01 (2017): 98–104. http://dx.doi.org/10.5262/tndt.2017.1001.16.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Babayev, F. "Dispersion Analysis of Risk Factors for Chronic Kidney Disease." Bulletin of Science and Practice 6, no. 9 (2020): 174–81. http://dx.doi.org/10.33619/2414-2948/58/16.

Повний текст джерела

Анотація:

Risk factors for chronic kidney disease include diabetes mellitus, hypertension, autoimmune diseases, urinary tract infections, urolithiasis, urinary tract obstruction, toxic effects of drugs, cardiovascular diseases, etc. In order to study the effect of several risk factors on the development of chronic kidney disease and the role of each factor in comparison with the proportion of their effect on the final result, a dispersion analysis was carried out. It was revealed that the development of chronic kidney disease in men is influenced by diabetes mellitus (H/h=+0.69), diabetic nephropathy (H

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Kanduri, Swetha R., Karthik Kovvuru, Panupong Hansrivijit, et al. "SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease." Journal of Clinical Medicine 9, no. 9 (2020): 2723. http://dx.doi.org/10.3390/jcm9092723.

Повний текст джерела

Анотація:

Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive effects of SGLT2i are centered on multiple mechanisms, including glycosuric effects, tubule—glomerular feedback, antioxidant, anti-fibrotic, natriuretic, and reduction in cortical hypoxia, alteration in energy metabolism. Concurrently, multiple kidney and cardiovascular outcome studies have reporte

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Kearney, Jessica, and Luigi Gnudi. "The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes." Pharmaceutics 15, no. 5 (2023): 1343. http://dx.doi.org/10.3390/pharmaceutics15051343.

Повний текст джерела

Анотація:

The diabetes epidemic and the increasing number of patients with diabetic chronic vascular complications poses a significant challenge to health care providers. Diabetic kidney disease is a serious diabetes-mediated chronic vascular complication and represents a significant burden for both patients and society in general. Diabetic kidney disease not only represents the major cause of end stage renal disease but is also paralleled by an increase in cardiovascular morbidity and mortality. Any interventions to delay the development and progression of diabetic kidney disease are important to reduc

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Irma, Larios Jiménez. "Prevalence of chronic kidney disease by stage in diabetic patients." Archives of Renal Diseases and Management 3, no. 2 (2017): 045–47. https://doi.org/10.17352/2455-5495.000028.

Повний текст джерела

Анотація:

Fundamentals. Diabetes  mellitus  2  is  a  chronic  disease  with  an  increasing  prevalence  in  recent  years,  it  is  expected  that  by  2030  there  will  be  336  million  diabetics  worldwide,  and  the  increase  in  life expectancy  will  influence  the  presentation  of  chronic  complications,  including  chronic  kidney  disease with  a  prevalence  of 

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Dr., Amit Kumar Verma. "Periodontal Disease with Diabetes or Diabetes Kidney Disease." International Journal of Trend in Scientific Research and Development 3, no. 1 (2018): 1043–51. https://doi.org/10.31142/ijtsrd19176.

Повний текст джерела

Анотація:

diseases such as diabetes and atherosclerosis, cardiovascular diseases, and even chronic kidney disease CKD through low grade systemic inflammation, although no causality can be drawn. CKD is an increasing problem worldwide, and has adverse effects on oral health. The main risk factors of CKD are diabetes mellitus DM , hypertension and obesity. Diabetic nephropathy is the main reason for entering dialysis in Finland and cardiovascular diseases CVD play a crucial role in mortality among CKD patients. The hypotheses were that diabetic nephropathy patients have worse oral health than other CKD pa

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Amaral, Liliany Souza de Brito, Cláudia Silva Souza, Hernando Nascimento Lima, and Telma de Jesus Soares. "Influence of exercise training on diabetic kidney disease: A brief physiological approach." Experimental Biology and Medicine 245, no. 13 (2020): 1142–54. http://dx.doi.org/10.1177/1535370220928986.

Повний текст джерела

Анотація:

Sedentary lifestyle is associated with increased incidence of diabetes mellitus, whereas exercise training improves metabolic control and therefore may contribute to prevention of various chronic complications. Diabetic kidney disease is the most common microvascular complication of diabetes mellitus, and is associated with increased mortality from cardiovascular disease in diabetic patients. The literature highlights oxidative stress, renal inflammation, and activation of the renin-angiotensin-aldosterone system as the main pathophysiological mechanisms underlying tissue damage, extracellular

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Agaçi, F., S. Tafaj, E. Xhardo, and L. Suraj. "Urinary tract infections and asymptomatic bacteriuria in diabetic patients with pulmonary diseases." Problems of Endocrine Pathology 67, no. 1 (2019): 7–17. http://dx.doi.org/10.21856/j-pep.2019.1.01.

Повний текст джерела

Анотація:

Urinary tract infections and asymptomatic bacteriuria, are more frequent in diabetic patients, especially in those with type 2 diabetes, than in subjects without diabetes. Diabetic people are more risked than persons without diabetes for acute infections of upper urinary tract (pyelonephritis). Some investigators, on the other hand, observed that signs and symptoms of these infections are more severe in diabetics than in non-diabetic people [6–8]. Urinary tract infections can cause severe kidney injuries and, consequently, can lead to chronic kidney disease (chronic renal insufficiency). Conce

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Sigitova, O. N., A. R. Bogdanova, and T. Yu Kim. "The structure and features of the course of chronic kidney disease in patients with coronary heart disease and comorbid diseases." Kazan medical journal 102, no. 5 (2021): 606–13. http://dx.doi.org/10.17816/kmj2021-606.

Повний текст джерела

Анотація:

Aim. To investigate the prevalence, structure, and features of the course of chronic kidney disease (CKD) in patients with coronary heart disease (CHD) associated with comorbid diseases. Methods. The observation group consisted of 257 patients of the Interregional Clinical Diagnostic Center (Kazan) with coronary heart disease (20142018): 183 males and 74 females, aged from 38 to 95 years (mean age 61.80.6). Observation program: clinical examination; serum creatinine and lipid profiles, the albumin/creatinine ratio in a single portion of urine, morning urine osmolality, glomerular filtrat

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Piko, Nejc, Sebastjan Bevc, Radovan Hojs, and Robert Ekart. "Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease." Pharmaceuticals 17, no. 4 (2024): 418. http://dx.doi.org/10.3390/ph17040418.

Повний текст джерела

Анотація:

Diabetic kidney disease is a frequent microvascular complication of diabetes and is currently the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Although the prevalence of other complications of diabetes is falling, the number of diabetic patients with end-stage kidney disease in need of kidney replacement therapy is rising. In addition, these patients have extremely high cardiovascular risk. It is more than evident that there is a high unmet treatment need in patients with diabetic kidney disease. Finerenone is a novel nonsteroidal mineralocorticoid receptor a

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Currie, Gemma, Bill Mullen, and Christian Delles. "Diabetic kidney disease: a case for precision medicine?" Biochemist 38, no. 1 (2016): 22–26. http://dx.doi.org/10.1042/bio03801022.

Повний текст джерела

Анотація:

A key element in the management of patients with chronic diseases is the prevention of complications. In patients with diabetes mellitus, diabetic kidney disease (DKD) is among the most dangerous complications. Approaches to prevent or at least delay the onset and progression of DKD are widely used in clinical practice, but are associated with adverse effects in some patients. In this article we use the example of DKD to describe how the concept of “Personalized Medicine” can be applied to chronic diseases and preventative medicine.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Chernyaeva, A., and M. Mykytyuk. "CYSTATIN C AS A MARKER OF KIDNEY FUNCTION IN PATIENTS WITH DIABETES MELLITUS AND PURINE METABOLISM DISORDERS." Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 21, no. 2 (2021): 87–92. http://dx.doi.org/10.31718/2077-1096.21.2.87.

Повний текст джерела

Анотація:

Chronic kidney disease is a pressing issue for healthcare systems over the world; its prevalence has reached 13% in Western countries. In recent years, cystatin C has been proposed as a more reliable endogenous marker of renal function, especially for the diagnosis of initial changes in glomerular filtration rate. The aim of this study is to analyze the signs of chronic kidney disease in patients with type 2 diabetes mellitus depending on the level of uricemia by using cystatin C in real clinical practice. The study included 127 patients with type 2 diabetes mellitus (mean age = 60.0 years [52

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Lahens, Nicholas F., Mahboob Rahman, Jordana B. Cohen, et al. "Time-specific associations of wearable sensor-based cardiovascular and behavioral readouts with disease phenotypes in the outpatient setting of the Chronic Renal Insufficiency Cohort." DIGITAL HEALTH 8 (January 2022): 205520762211079. http://dx.doi.org/10.1177/20552076221107903.

Повний текст джерела

Анотація:

Patients with chronic kidney disease are at risk of developing cardiovascular disease. To facilitate out-of-clinic evaluation, we piloted wearable device-based analysis of heart rate variability and behavioral readouts in patients with chronic kidney disease from the Chronic Renal Insufficiency Cohort and controls (n = 49). Time-specific partitioning of heart rate variability readouts confirm higher parasympathetic nervous activity during the night (mean RR at night 14.4 ± 1.9 ms vs. 12.8 ± 2.1 ms during active hours; n = 47, analysis of variance (ANOVA) q = 0.001). The α2 long-term fluctuatio

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Hong, Ruo-Wei, Kai-Hsiang Shu, I.-Yu Chen, Fang-Yun Lay, Yi-Fang Chuang, and Yen-Ling Chiu. "Progressive immunosenescence in diabetic chronic kidney disease." Journal of Immunology 204, no. 1_Supplement (2020): 145.12. http://dx.doi.org/10.4049/jimmunol.204.supp.145.12.

Повний текст джерела

Анотація:

Abstract Type 2 diabetes is an important challenge given the worldwide epidemic and is the most important cause of end-stage renal disease in developed countries. It is known that patients with end-stage renal disease and advanced renal failure suffer from immunosenescence and premature T cell aging, but whether such changes develop in patients with less severe chronic kidney disease (CKD) is unclear. We investigated level of immunosenescence in 770 Patients with type 2 diabetes with different levels of renal function. Consistent with previous observations in the general population, both T and

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Muhammad Tahir Younas, Shoaib Mukhtar, Sabeeha Yousaf, Hira Niazi, and Sana Younas. "Microalbuminuria In Newly Diabetes Mellitus Patients: Diagnosis, Screening and Increasing Public Awareness." BMC Journal of Medical Sciences 4, no. 1 (2023): 92–95. https://doi.org/10.70905/bmcj.04.01.075.

Повний текст джерела

Анотація:

Abstract Objective: To promote public awareness about preventing chronic kidney disease by determining the prevalence and diagnosis of microalbuminuria in people with newly diagnosed diabetes. Methodology: Cross Sectional Survey and analysis study was conducted in Department of Medicine PAF Hospital Islamabad from 1st January 2021 to 30th June 2021. A total of 111 newly diagnosed diabetic patients of both genders were included. All patients were sent to same hospital laboratory for urine test by Pathologist aiming microalbuminuria status. Data was collected regarding microalbuminuria from all

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Thomas, Purnima Eliz, Pushpalatha M, Shajee Sivasankaran Nair, and Sajeevan Kundil Chandran. "Comparison of Metabolic Bone Markers in Diabetic and Non-Diabetic Chronic Kidney Diseases in Government Medical College, Thrissur, Kerala, India." Journal of Evidence Based Medicine and Healthcare 8, no. 29 (2021): 2578–83. http://dx.doi.org/10.18410/jebmh/2021/476.

Повний текст джерела

Анотація:

BACKGROUND The term ‘Chronic Kidney Disease-Mineral and Bone Disorder’ (CKD-MBD) has been used to describe clinically, the abnormalities in the bone and mineral metabolism associated with CKD. In CKD, serum levels of metabolic bone disease markers generally reflect a high bone turnover state (hyperphosphatemia, hypocalcaemia, hypersecretion of PTH, increased ALP). However, it has been noted that in diabetic CKD patients on regular haemodialysis, there is an impaired secretion of PTH when compared to the non-diabetics on haemodialysis. In this study we intend to evaluate the serum bone markers

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Stanigut, Alina Mihaela, Liliana Tuta, Camelia Pana, et al. "Autophagy and Mitophagy in Diabetic Kidney Disease—A Literature Review." International Journal of Molecular Sciences 26, no. 2 (2025): 806. https://doi.org/10.3390/ijms26020806.

Повний текст джерела

Анотація:

Autophagy and mitophagy are critical cellular processes that maintain homeostasis by removing damaged organelles and promoting cellular survival under stress conditions. In the context of diabetic kidney disease, these mechanisms play essential roles in mitigating cellular damage. This review provides an in-depth analysis of the recent literature on the relationship between autophagy, mitophagy, and diabetic kidney disease, highlighting the current state of knowledge, existing research gaps, and potential areas for future investigations. Diabetic nephropathy (DN) is traditionally defined as a

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Hoogeveen, Ellen K. "The Epidemiology of Diabetic Kidney Disease." Kidney and Dialysis 2, no. 3 (2022): 433–42. http://dx.doi.org/10.3390/kidneydial2030038.

Повний текст джерела

Анотація:

Globally, the incidence and prevalence of diabetes mellitus has risen dramatically, owing mainly to the increase in type 2 diabetes mellitus (T2DM). In 2021, 537 million people worldwide (11% of the global population) had diabetes, and this number is expected to increase to 783 million (12%) by 2045. The growing burden of T2DM is secondary to the pandemic of obesity, which in turn has been attributed to increased intake of processed food, reduced physical activity, and increased sedentary behaviour. This so-called western lifestyle is related with the global increase in urbanization and techno

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Metzinger, Laurent, Juan Antonio Moreno, and Valérie Metzinger-Le Meuth. "The Role of Non-Coding RNAs in Kidney Diseases." International Journal of Molecular Sciences 23, no. 12 (2022): 6624. http://dx.doi.org/10.3390/ijms23126624.

Повний текст джерела

Анотація:

Renal diseases include different pathologies, such as acute kidney injury (AKI), chronic kidney disease (CKD), end-stage renal disease (ESRD), diabetic nephropathy (DN), kidney cancer, polycystic kidney disease, etc [...]

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Yahr, Jordana, Juan Calle, and Jonathan J. Taliercio. "A renaissance in the treatment of diabetic kidney disease, hypertension in chronic kidney disease, and beyond." Journal of Osteopathic Medicine 122, no. 1 (2021): 55–63. http://dx.doi.org/10.1515/jom-2021-0150.

Повний текст джерела

Анотація:

Abstract Chronic kidney disease (CKD) affects approximately 15% of the US population and is associated with significant cardiovascular morbidity and mortality. The two leading causes of end stage kidney disease are hypertension and diabetes mellitus, both of which are modifiable risk factors. The cornerstones of CKD care include early detection, management of associated risk factors, modification of cardiovascular disease risk, slowing progression of disease, and management of complications including anemia, acid base disturbance, and mineral and bone disorders. For the last 20 years, renin-an

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Venkatesan, Kirthika, Mabel Cheryeth, Anna Tintu Verghese, et al. "Finerenone and diabetic renal disease: a narrative review." Journal of Prescribing Practice 6, no. 11 (2024): 474–80. http://dx.doi.org/10.12968/jprp.2024.0010.

Повний текст джерела

Анотація:

Overactivation of mineralocorticoid receptors occurs in cardiorenal diseases. Many patients with type 2 diabetes often progress to chronic kidney disease (CKD) and require dialysis. Finerenone is the first oral non-steroidal mineralocorticoid receptor antagonist used in patients with diabetic kidney disease and heart failure. Finerenone (Kerendia®) is more potent than spironolactone in reducing inflammation and fibrosis in CKD and exerts its effect equally on the heart and kidneys, improving cardiovascular outcomes. Research demonstrates that finerenone improves proteinuria and glomerular filt

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Nogueira, Cláudia, Selma Souto, Eduardo Vinha, Daniel Carvalho-Braga, and Davide Carvalho. "Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease." HORMONES 12, no. 4 (2013): 483–94. http://dx.doi.org/10.14310/horm.2002.1436.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Dănciulescu Miulescu, Rucsandra, Marius Cristian Neamţu, Denisa Margină, Cătălina Poiană, and Diana Loreta Păun. "Associations between thyroid dysfunction and chronic kidney disease." Romanian Journal of Diabetes Nutrition and Metabolic Diseases 21, no. 1 (2014): 37–42. http://dx.doi.org/10.2478/rjdnmd-2014-0006.

Повний текст джерела

Анотація:

Abstract Background and Aims. The interactions between kidney and thyroid functions are well established: thyroid hormones are necessary for the maintenance of electrolyte and water homeostasis and kidney is involved in the regulation of thyroid hormones metabolism. The aim of our study was to estimate the prevalence of thyroid dysfunction in patients with diabetes mellitus and chronic kidney disease (CKD). Material and Method. 23 patients with diabetes mellitus and CKD in pre-dialysis phase were recruited for this study. All subjects were investigated with thyroid ultrasound and laboratory te

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Game, Frances. "diabetic foot and renal disease." British Journal of Diabetes 25, no. 1 (2025): 38–40. https://doi.org/10.15277/bjd.2025.480.

Повний текст джерела

Анотація:

Diabetic foot disease is one of the most costly complications of diabetes in the UK, and frequently co-occurs with chronic kidney disease (CKD), including end-stage renal disease, in people with diabetes. In addition to the common pathologies underlying each complication of diabetes it is not clear whether each may have an influence on the other. Those with end- stage renal disease are at particular risk of the development of diabetic foot disease, and this risk increases dramatically when renal replacement therapy commences. However, it is now also recognised that the presence of a diabetes-r

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Yakush Williams, Jessica K. "Management Strategies for Patients with Diabetic Kidney Disease and Chronic Kidney Disease in Diabetes." Nursing Clinics of North America 52, no. 4 (2017): 575–87. http://dx.doi.org/10.1016/j.cnur.2017.07.007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!